- Legend Biotech Corporation recently completed a US$225.995 million follow-on equity offering of 7,700,000 American Depositary Shares at US$29.35 each, soon after reporting first-in-human proof-of-concept data for its investigational in vivo CD19/CD20 dual-targeting CAR-T therapy LB2501 in relapsed or refractory B-cell non-Hodgkin lymphoma.
- Early Phase 1 results showed a single infusion of LB2501 achieved dose-dependent in vivo CAR-T expansion without lymphodepletion and delivered high response rates with a favorable safety profile, highlighting the potential of in vivo T-cell engineering to reshape cell therapy delivery.
- Against this backdrop, we’ll examine how LB2501’s early in vivo CAR-T proof-of-concept findings could influence Legend Biotech’s broader investment narrative.
We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Legend Biotech Investment Narrative Recap
To own Legend Biotech today, you need to believe CARVYKTI can fund a broader cell therapy pipeline while new programs like LB2501 eventually reduce single‑product dependence. The LB2501 proof‑of‑concept data and the US$225.995 million equity raise strengthen the company’s capacity to invest, but they do not immediately resolve the near term risk that CARVYKTI concentration, ongoing losses and rising competition remain the key swing factors.
The follow‑on equity offering is the most relevant recent announcement here. It materially boosts Legend’s cash resources just as LB2501 delivers encouraging early clinical data, giving the company more room to fund expanded trials and manufacturing capabilities. That extra capital can support the next set of clinical readouts and potential label or pipeline expansions that many investors are watching closely as the next major milestones.
However, while the science is progressing, investors should also be aware that...
Read the full narrative on Legend Biotech (it's free!)
Legend Biotech's narrative projects $2.1 billion revenue and $501.1 million earnings by 2029.
Uncover how Legend Biotech's forecasts yield a $57.24 fair value, a 95% upside to its current price.
Exploring Other Perspectives
While LB2501’s data hint at a broader future beyond CARVYKTI, the most bearish analysts were still modeling only US$1.9 billion revenue and US$103.5 million earnings by 2029, reminding you that expectations and risk views can differ widely and may shift again as this new information is absorbed.
Explore 5 other fair value estimates on Legend Biotech - why the stock might be worth over 4x more than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Legend Biotech research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Legend Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Legend Biotech's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
- Explore 31 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com